Iterum Therapeutics Plc (NASDAQ:ITRM) traded at $1.99 at close of the session on current trade day and made an upward move of 9.94% on its previous day’s price.
Looking at the stock we see that its previous close was $1.81 and the beta (5Y monthly) reads 2.248 with the day’s price range being $1.78 – $2.005. In terms of its 52-week price range, ITRM has a high of $2.50 and a low of $0.81. The company’s stock has gained about 5.85% over that past 30 days.
Iterum Therapeutics Plc has a market cap of $55.99 million and is expected to release its quarterly earnings report in December. Estimates by analysts give the company expected earnings per share (EPS) of -0.24, with the EPS growth for the year raised at -1.03 for current year and -1.03 for next year.
On the other hand, looking at the outlook for the ITRM stock, short term indicators assign the stock an average of 100% Buy, while medium term indicators assign it an average of Hold.
Based on estimates by 1 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 0 have rated the Iterum Therapeutics Plc (ITRM) stock as a Hold, while 1 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note the current price level is 37.86% off its SMA20 and 61.60% from its 50-day simple moving average. The RSI (14) is pointing at 73.38 while the volatility over the past week is 12.20% and jumps to 12.31% over the past one month. The beta value is 2.34, while the average true range (ATR) is currently pointing at 0.17.
Coming back to Iterum Therapeutics Plc (NASDAQ:ITRM), we note that the average 3-month trading volume was 2.48 million, while that of the preceding 10-day period stands at 1.1 million. Current shares outstanding are 27.52 million.
The insiders hold 3.33% of the company’s shares while institutions hold 6.16%. The data shows that short shares as of 2024-10-31, stood at 2.53 million at a short ratio of 0.46. This represents a 1153.00 short interest in shares outstanding on 2024-10-31. Shares short rose in October from the previous month at 0.22 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock 1.02% up in year-to-date price movement.
